Microbiome refers to the collection or community of microbes. Microbial community that presented in our body has major impact on the body functions from digestion to immune conditions. Millions of microbes are present in our digestive tract, oral cavity, respiratory mucosa, skin and other parts of the body. In recent years, research on microbiome increased over the years to know benefits associated with microbes on the host. In microbiome therapeutics probiotics, prebiotics and synbiotics play a vital role in diagnosis, prevention, and treatment of various disease conditions. Probiotics are microorganisms such as bacteria, yeasts that provide health benefits when they consumed. Prebiotics are non-digestible carbohydrate that helps in growth of microbes that are present in the body. The combination of probiotics and prebiotics called as Synbiotics. However, till date, there was no microbiome related product in the market that was approved by U.S. FDA to treat any specific indication. The most beneficial factor for microbiome therapeutics is they didn’t cause any side effects unlike the drug molecules as they already reside in the body. Hence, they are gaining traction from many small and big companies to explore its benefits on various disease indications like prevention of oral biofilm, Crohn’s disease, Irritable bowel syndrome conditions that don’t have any proper treatment. Vedanta Biosciences, a startup working on Clostridium strains (VE-202) to treat IBD and Crohn’s disease conditions. In January 2015, Johnson and Johnson signed the license agreement with Vedanta Biosciences to acquire rights for the investigational drug to treat IBD conditions. Synologic involved in the development of medicines from microbiome platform collaborated with AbbVie to develop the drug for inflammatory bowel disease.
Discover more at: Open PR